Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

J. B. Engel, Andrew V Schally, S. Buchholz, S. Seitz, G. Emons, O. Ortmann

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Receptors luteinizing hormone-releasing hormone (LHRH) are expressed in about 80 % of human endometrial and ovarian cancers and account for more than 50 % of breast cancers including triple negative breast cancers. Apart from the pituitary and reproductive organs, no other organs or hematopoietic stem cells express LHRH (GnRH) receptors. Thus, these receptors can be regarded as an ideal target for a personalized medicine approach in cancer therapy. AEZS-108 (formerly known as AN-152) in which doxorubin is linked to the LHRH agonist [D-Lys6]LHRH, appears to be the most advanced compound in late stage clinical development. Results: of phase I and phase II clinical trials in patients with gynecological cancers demonstrated anticancer activity without any cardiotoxicity even in highly pretreated patients. AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients.

Original languageEnglish
Pages (from-to)437-442
Number of pages6
JournalArchives of Gynecology and Obstetrics
Volume286
Issue number2
DOIs
StatePublished - Aug 1 2012

Fingerprint

LHRH Receptors
Endometrial Neoplasms
Gonadotropin-Releasing Hormone
Ovarian Neoplasms
Breast Neoplasms
Drug Therapy
Triple Negative Breast Neoplasms
Precision Medicine
Phase II Clinical Trials
Hematopoietic Stem Cells
Neoplasms
Peptides
Membranes
lysine(6)-doxorubicin LHRH

Keywords

  • AEZS-108
  • Breast cancer
  • Doxorubicin
  • Endometrial cancer
  • EP-100
  • LHRH receptor-positive cancers
  • Ovarian cancer
  • Targeted chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). / Engel, J. B.; Schally, Andrew V; Buchholz, S.; Seitz, S.; Emons, G.; Ortmann, O.

In: Archives of Gynecology and Obstetrics, Vol. 286, No. 2, 01.08.2012, p. 437-442.

Research output: Contribution to journalArticle

@article{395f26aa43044979b225b5b481c99cea,
title = "Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)",
abstract = "Receptors luteinizing hormone-releasing hormone (LHRH) are expressed in about 80 {\%} of human endometrial and ovarian cancers and account for more than 50 {\%} of breast cancers including triple negative breast cancers. Apart from the pituitary and reproductive organs, no other organs or hematopoietic stem cells express LHRH (GnRH) receptors. Thus, these receptors can be regarded as an ideal target for a personalized medicine approach in cancer therapy. AEZS-108 (formerly known as AN-152) in which doxorubin is linked to the LHRH agonist [D-Lys6]LHRH, appears to be the most advanced compound in late stage clinical development. Results: of phase I and phase II clinical trials in patients with gynecological cancers demonstrated anticancer activity without any cardiotoxicity even in highly pretreated patients. AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients.",
keywords = "AEZS-108, Breast cancer, Doxorubicin, Endometrial cancer, EP-100, LHRH receptor-positive cancers, Ovarian cancer, Targeted chemotherapy",
author = "Engel, {J. B.} and Schally, {Andrew V} and S. Buchholz and S. Seitz and G. Emons and O. Ortmann",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s00404-012-2335-1",
language = "English",
volume = "286",
pages = "437--442",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

AU - Engel, J. B.

AU - Schally, Andrew V

AU - Buchholz, S.

AU - Seitz, S.

AU - Emons, G.

AU - Ortmann, O.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Receptors luteinizing hormone-releasing hormone (LHRH) are expressed in about 80 % of human endometrial and ovarian cancers and account for more than 50 % of breast cancers including triple negative breast cancers. Apart from the pituitary and reproductive organs, no other organs or hematopoietic stem cells express LHRH (GnRH) receptors. Thus, these receptors can be regarded as an ideal target for a personalized medicine approach in cancer therapy. AEZS-108 (formerly known as AN-152) in which doxorubin is linked to the LHRH agonist [D-Lys6]LHRH, appears to be the most advanced compound in late stage clinical development. Results: of phase I and phase II clinical trials in patients with gynecological cancers demonstrated anticancer activity without any cardiotoxicity even in highly pretreated patients. AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients.

AB - Receptors luteinizing hormone-releasing hormone (LHRH) are expressed in about 80 % of human endometrial and ovarian cancers and account for more than 50 % of breast cancers including triple negative breast cancers. Apart from the pituitary and reproductive organs, no other organs or hematopoietic stem cells express LHRH (GnRH) receptors. Thus, these receptors can be regarded as an ideal target for a personalized medicine approach in cancer therapy. AEZS-108 (formerly known as AN-152) in which doxorubin is linked to the LHRH agonist [D-Lys6]LHRH, appears to be the most advanced compound in late stage clinical development. Results: of phase I and phase II clinical trials in patients with gynecological cancers demonstrated anticancer activity without any cardiotoxicity even in highly pretreated patients. AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients.

KW - AEZS-108

KW - Breast cancer

KW - Doxorubicin

KW - Endometrial cancer

KW - EP-100

KW - LHRH receptor-positive cancers

KW - Ovarian cancer

KW - Targeted chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84864422677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864422677&partnerID=8YFLogxK

U2 - 10.1007/s00404-012-2335-1

DO - 10.1007/s00404-012-2335-1

M3 - Article

C2 - 22555802

AN - SCOPUS:84864422677

VL - 286

SP - 437

EP - 442

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 2

ER -